11 July 2025
Image Credits: The Pharma Letter
Enterome, a leading clinical-stage company known for its high-scale development of Oncomimics immunotherapies for cancer, has raised $19 million in fresh new financing for the advancement of its popular clinical program, EO2463 Oncomimics immunotherapy. This therapy treats indolent non-Hodgkin lymphoma (INHL). The raised funds come from two different investors within Enterome. The Institute for Follicular Lymphoma Innovation (IFLI) initiated a new investment of $9 million. An existing specialist investor, along with the LEUKEMIA & Lymphoma Society's therapy acceleration program (LLS TAP), invested $10 million. The intention behind this new funding was to expand and officialize the current Phase ½ Sidney clinical trial of EO2463. It will also need candidates for a registrational trial.
Investors play a crucial role in the healthcare market. The market stands a chance to explore and compete with the valuable support of the investors. For Enterome, the new US investor IFLI, a leading non-profit foundation, and other existing prominent shareholders supported the company in raising funds to finalize its existing SIDNEY clinical trial. The efforts to launch and develop innovation are possible with the government's and investors' contributions.
Enterome's recent announcement states that it will introduce new data highlighting EO2463’s positive impact after the merged testing with the standard of care in patients suffering from refractory Inhl and relapsed. The result will be unveiled at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21. At ASCO in 2024, the same patient population experienced a positive impact and found EO2463 treatment beneficial. It also received huge support from biomarker analyses. The company currently holds meetings with both EMA (Scientific advice) and FDA (Type C meeting) to receive regulatory confirmation and registration for commercializing authorization in Inhl.
Enterome’s chief executive officer, Pierre Belichard, said, “The leading blood cancer investor IFLI’s investment in this financing elaborates the formalization of the company’s new and existing investors in OncoMimics (a blood and solid tumor cancer). Enterome is currently working on presenting accurate clinical proof of EO2463 monotherapy data in various INHL patients from the phase ½ SIDNEY clinical trial. The financing will allow us to continue with the SIDNEY trial of EO2463 and introduce the first crucial phase 3 trial.”
MD Chief Medical Officer at IFLI, Michel Azoulay, said, “This investment intersects with IFLI’s mission to leverage the development of precision biomarkers and innovative therapies for follicular lymphoma."
11 July 2025
11 July 2025
11 July 2025
11 July 2025